GKOSHealthcare · Medical DevicesThe 14 Wall Street analysts covering Glaukos Corp. hold a median 12-month price target of $200 — +19.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Glaukos Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Issuance (54): The company has been issuing shares or taking on financing, diluting existing holders.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GKOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.1% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | BTIG | Maintains | Buy | $202 → $205 |
| 22 Sept 2026 | Jefferies | Maintains | Buy | — |
| 22 Sept 2026 | Jefferies | Maintains | Buy | $190 → $210 |
| 20 Aug 2026 | BTIG | Maintains | Buy | $193 → $202 |
| 20 Aug 2026 | BTIG | Maintains | Buy | — |
| 30 July 2026 | BTIG | Maintains | Buy | $164 → $193 |
| 30 July 2026 | BTIG | Maintains | Buy | — |
| 30 July 2026 | Citigroup | Maintains | Buy | $175 → $188 |
| 30 July 2026 | Citigroup | Maintains | Buy | — |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $168 → $195 |
| 30 July 2026 | Jefferies | Maintains | Buy | — |
| 30 July 2026 | Needham | Maintains | Buy | $150 → $201 |
| 30 July 2026 | Needham | Maintains | Buy | — |
| 30 July 2026 | Piper Sandler | Reiterates | Overweight | $165 → $195 |
| 30 July 2026 | Piper Sandler | Reiterates | Overweight | — |
| 30 July 2026 | Stifel | Maintains | Buy | — |
| 30 July 2026 | Stifel | Maintains | Buy | $175 → $190 |
| 30 July 2026 | Truist Securities | Maintains | Buy | $180 → $215 |
| 30 July 2026 | Truist Securities | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GKOS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Glaukos Corp. returned +96.8% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 10% of US stocks
Cheaper than 6% of US stocks
Cheaper than 98% of US stocks
Higher than 86% of US stocks
Higher than 74% of US stocks
Higher than 92% of US stocks
Higher than 25% of US stocks
Higher than 13% of US stocks
Higher than 29% of US stocks
Higher than 32% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Glaukos Corp. has a market value of $9.9B and an enterprise value of $9.6B.
Revenue in the twelve months to 30 June 2026: $612.8M. The latest quarter grew 49.5% year on year.
Net income over the same four quarters: −$188.0M, a −30.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.25.
Free cash flow in the twelve months to 30 June 2026: −$28.8M.
Trailing P/E: −51.2×; forward P/E: 320.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Glaukos Corp. employs 1,094 people — $560K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Glaukos Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Glaukos shares gained 36.8% over six months. The cited drivers include strong sales, expansion of iDose TR and Epioxa, higher guidance, and promising clinical developments.
Why it matters — These factors are presented as the context behind the share-price gain and may be relevant to watchers tracking Glaukos’s business and clinical developments.
The article describes Glaukos shifting from a single-product reimbursement story to a broader ophthalmic pharmaceutical platform, citing Q2 net sales growth of 50% year over year to $185.6 million, an 85% non-GAAP gross margin and breakeven P&L. Management raised 2026 net sales guidance to $680–700 million.
Why it matters — The second J-coded drug and updated sales guidance are central to the article’s view of Glaukos’s expanding product mix and operating performance.
Glaukos expanded its retinal pipeline through a licensing deal for RO-104 and exclusive rights to the RevMod platform. Shares declined 6.3% following the news.
Why it matters — The deal adds licensed assets and platform rights to Glaukos’s retinal pipeline, while the excerpt also notes a share decline after the announcement.
Glaukos reported successful topline outcomes from its latest Phase 4 clinical study of a novel eye therapy, with the headline citing superior intraocular pressure reduction.
Why it matters — The reported study outcome is relevant to GKOS watchers tracking the company’s clinical development of ophthalmic therapies.
Glaukos announced positive topline results from Phase 4 trial GLK-101-04, which evaluated iDose TR administered alongside cataract surgery versus cataract surgery alone in patients with open-angle glaucoma.
Why it matters — The trial results concern iDose TR in combination with cataract surgery, an evaluation relevant to Glaukos’s glaucoma therapy program.
The 14 Wall Street analysts covering Glaukos Corp. have a median 12-month price target of $200, with estimates ranging from $172 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Glaukos Corp., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Glaukos Corp. 88 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Glaukos Corp. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +19.1% from the last close, and Ticker Nerd's factor model ranks Glaukos Corp. 88 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Glaukos Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GKOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $172 to $225 over the next 12 months.
Glaukos Corp. returned +96.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases.
The most recent item we track (Zacks Investment Research, 14 Oct 2026): "Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?". Glaukos shares gained 36.8% over six months. The cited drivers include strong sales, expansion of iDose TR and Epioxa, higher guidance, and promising clinical developments.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release drug delivery systems, and bio-activated therapies designed to address chronic eye disease across multiple stages of care. The company serves ophthalmologists, surgeons, and healthcare providers with solutions intended to improve treatment options in both surgical and pharmaceutical settings. Glaukos Corp. is a specialized participant in the eye care market, combining medical devices and medicines to support procedures and therapies used in glaucoma management and corneal health.
CEO Mr. Thomas William Burns · 1,094 employees · United States · https://www.glaukos.com
